OR WAIT null SECS
October 20, 2021
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
October 19, 2021
COVID-19 travel restrictions have hindered the FDA’s ability to inspect European manufacturing facilities for bimekizumab, which is under review for the treatment of patients with psoriasis.
ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.
This low-dose formulation of Biktarvy is for younger children living with HIV.
October 18, 2021
Narsoplimab was under review at the FDA to treat a complication of stem cell transplants.
The agency cited an open inspection issue at a facility that performs analytical testing of drug substance.
Tyrvaya is a twice daily nasal spray, a first for the treatment of dry eye disease.
The FDA approved Lybalvi in June 2021 to treat schizophrenia and bipolar disorder.
October 17, 2021
Boehringer Ingelhiem will make Cyltezo available when its commercial license begins on July 1, 2023.
October 15, 2021
The committee’s two-day meeting resulted in recommended approvals for both J&J’s and Moderna’s COVID-19 booster.
